IBRX270416C00008000
IBRX Apr 16 2027 8.00 Call
optionOPRA
EODOct 12, 2026
4.16USD+69.796%(+1.71)20Vol96OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
8
Expiration
Apr 16, 2027
DTE
178d
Moneyness
ITM
Intrinsic
$0.48
IBRX 8 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $2.17 | +3.33% | 11 | 23 |
| Oct 30, 2026 | 10d | $1.42 | -29.00% | 8 | 45 |
| Nov 6, 2026 | 17d | $1.85 | -31.23% | 10 | 507 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $1.75 | -28.57% | 129 | 1,315 |
| Nov 27, 2026 | 38d | $1.90 | -25.49% | 2 | 11 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Mar 19, 2027 | 150d | $3.00 | -11.76% | 59 | 1,300 |
| Apr 16, 2027 | 178d | $4.16 | +69.80% | 20 | 96 |
| May 21, 2027 | 213d | $3.00 | +13.21% | 2 | 3 |
IBRX Nearby Strikes · Apr 16, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 2 C | $8.40 | +0.00% | 20 | 20 | ITM |
| 3 C | $5.90 | +11.53% | 10 | 50 | ITM |
| 4 C | — | — | 0 | 0 | ITM |
| 5 C | $5.70 | +9.62% | 2 | 25 | ITM |
| 6 C | $3.90 | +30.00% | 1 | 0 | ITM |
| 7 C | $4.48 | +0.00% | 11 | 11 | ITM |
| 8 C | $4.16 | +69.80% | 20 | 96 | ITM |
| 9 C | $3.40 | -12.82% | 1 | 42 | OTM |
| 10 C | $2.10 | -27.84% | 8 | 120 | OTM |
| 11 C | $2.48 | -0.80% | 1 | 98 | OTM |
| 12 C | $1.80 | -25.00% | 180 | 176 | OTM |
| 13 C | $2.11 | +24.12% | 40 | 44 | OTM |
| 14 C | $2.10 | +22.81% | 20 | 21 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.